Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
LODOXAMIDE
Alcon Laboratories (UK) Ltd
0.1 %w/v
Eye Drops Solution
2003-06-03
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0290/063/002 Case No: 2080568 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ALCON LABORATORIES (UK) LTD PENTAGON PARK, BOUNDARY WAY, HEMEL HEMPSTEAD, HERTFORDSHIRE HP2 7UD, ENGLAND an authorisation, subject to the provisions of the said Regulations, in respect of the product ALOMIDE ALLERGY 0.1% W/V EYE DROPS, SOLUTION the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 06/07/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 06/07/2010_ _CRN 2080568_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alomide Allergy 0.1% w/v Eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Contains 0.1% w/v lodoxamide as lodoxamide trometamol. Excipient: contains 0.007% w/v benzalkonium chloride as benzalkonium chloride solution. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution (eye drops). A clear colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Alomide is indicated in the treatment of the ocular signs and symptoms of allergic conjunctivitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults and children (4 years and above): One or two drops Read the complete document